Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors - Zhang, He-Jian; Zhang, Xue-Hui; Liu, Jie; Sun, Lu-Ning; Shen, Yi-Wen; Zhou, Chen; Zhang, Hong-Wen; Xie, Li-Jun; Chen, Juan; Liu, Yun; Wang, Yong-Qing (Pharmacological research, 2020)
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology; CYP2C19; Gastric H+K+-ATPase; Humans; Pharmacodynamics; Pharmacogenomic Variants; Pharmacokinetics; Polymorphism; Proton pump inhibitors (PPIs); Proton Pump Inhibitors - pharmacokinetics; Proton Pump Inhibitors - pharmacology; homEMs; Dexlansoprazole (PubChem CID: 9578005); Esomeprazole (PubChem CID: 9568614); H. pylori; CYP2C19; AUC; CYP450; t1/2; PMs; SNPs; Lansoprazole (PubChem CID: 3883); UMs; Omeprazole (PubChem CID: 4594); Rabeprazole (PubChem CID: 5029); Gastric H+K+-ATPase; Cmax; Pharmacodynamics; MR; hetEMs; PPIs; Proton pump inhibitors (PPIs); Ilaprazole (PubChem CID: 214351); H+,K+-ATPase; PD; H2RAs; Pantoprazole (PubChem CID: 4679); PK; Pharmacokinetics; TpH>4 (%); Polymorphism; Gastric H(+)K(+)-ATPase